Nuvectis Pharma, Inc.NVCTNASDAQ
Loading
Operating Cash Flow Growth AcceleratingAccelerating
Percentile Rank58
3Y CAGR-17.4%
Year-over-Year Change
Year-over-year operating cash flow growth rate
3Y CAGR
-17.4%/yr
Quarterly compound
Percentile
P58
Within normal range
vs 3Y Ago
0.6x
Contraction
Streak
1 qtr
Consecutive growthAccelerating
| Period | Value |
|---|---|
| Q4 2025 | 11.57% |
| Q3 2025 | -33.47% |
| Q2 2025 | 19.33% |
| Q1 2025 | -69.33% |
| Q4 2024 | -2.54% |
| Q3 2024 | 20.40% |
| Q2 2024 | 30.70% |
| Q1 2024 | -13.19% |
| Q4 2023 | -18.68% |
| Q3 2023 | 20.55% |
| Q2 2023 | 14.53% |
| Q1 2023 | -35.86% |
| Q4 2022 | 20.52% |
| Q3 2022 | -73.97% |
| Q2 2022 | 17.33% |
| Q1 2022 | -188.28% |
| Q4 2021 | 75.89% |
| Q3 2021 | -10.35% |
| Q2 2021 | 0.00% |
| Q1 2021 | 0.00% |